Skip to main content

CORRECTION article

Front. Mol. Neurosci., 26 July 2023
Sec. Molecular Signalling and Pathways
Volume 16 - 2023 | https://doi.org/10.3389/fnmol.2023.1257836
This article is part of the Research Topic Neuromodulation and Rehabilitation Affiliated Release of Pathological Pain After Spinal Cord Injury View all 7 articles

Corrigendum: Network pharmacology integrated with experimental validation to explore the therapeutic role and potential mechanism of Epimedium for spinal cord injury

This article is a correction to:

  1. Network pharmacology integrated with experimental validation to explore the therapeutic role and potential mechanism of Epimedium for spinal cord injury

    1. Read original article
\r\nXuanhao Fu&#x;Xuanhao Fu†Boyuan Ma&#x;Boyuan Ma†Mengmeng Zhou&#x;Mengmeng Zhou†Yuelin ChengYuelin ChengLinyan LiuLinyan LiuShunli KanShunli KanChengjiang LiuChengjiang LiuXinyan ZhaoXinyan ZhaoSa FengSa FengHaoqiang ZhuHaoqiang ZhuWei HuWei HuZehua JiangZehua JiangRusen Zhu Rusen Zhu*
  • Department of Spine Surgery, Tianjin Union Medical Center, Tianjin, China

A corrigendum on
Network pharmacology integrated with experimental validation to explore the therapeutic role and potential mechanism of Epimedium for spinal cord injury

by Fu, X., Ma, B., Zhou, M., Cheng, Y., Liu, L., Kan, S., Liu, C., Zhao, X., Feng, S., Zhu, H., Hu, W., Jiang, Z., and Zhu, R. (2023). Front. Mol. Neurosci. 16:1074703. doi: 10.3389/fnmol.2023.1074703

In the published article, there was an error in affiliation “1”. Instead of “Tianjin People's Hospital”, it should be “Tianjin Union Medical Center”.

Due to the change of the name of our institution from “Tianjin People's Hospital” to “Tianjin Union Medical Center”, we propose to correct the original institution name.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: spinal cord injury, Epimedium, network pharmacology, molecular docking, pharmacological mechanism

Citation: Fu X, Ma B, Zhou M, Cheng Y, Liu L, Kan S, Liu C, Zhao X, Feng S, Zhu H, Hu W, Jiang Z and Zhu R (2023) Corrigendum: Network pharmacology integrated with experimental validation to explore the therapeutic role and potential mechanism of Epimedium for spinal cord injury. Front. Mol. Neurosci. 16:1257836. doi: 10.3389/fnmol.2023.1257836

Received: 13 July 2023; Accepted: 17 July 2023;
Published: 26 July 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Fu, Ma, Zhou, Cheng, Liu, Kan, Liu, Zhao, Feng, Zhu, Hu, Jiang and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Rusen Zhu, zrsspine@163.com

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.